These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38362837)

  • 1. Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.
    Robbrecht D; Grob JJ; Bechter O; Simonelli M; Doger B; Borbath I; Butler MO; Cheng T; Romano PM; Pons-Tostivint E; Di Nicola M; Curigliano G; Ryu MH; Rodriguez-Vida A; Schadendorf D; Garralda E; Abbadessa G; Demers B; Amrate A; Wang H; Lee JS; Pomponio R; Wang R
    Clin Transl Sci; 2024 Feb; 17(2):e13736. PubMed ID: 38362837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study.
    Baranda JC; Robbrecht D; Sullivan R; Doger B; Santoro A; Barve M; Grob JJ; Bechter O; Vieito M; de Miguel MJ; Schadendorf D; Johnson M; Pouzin C; Cantalloube C; Wang R; Lee J; Chen X; Demers B; Amrate A; Abbadessa G; Hodi FS
    Clin Transl Sci; 2024 Jun; 17(6):e13854. PubMed ID: 38898592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade.
    Greco R; Qu H; Qu H; Theilhaber J; Shapiro G; Gregory R; Winter C; Malkova N; Sun F; Jaworski J; Best A; Pao L; Hebert A; Levit M; Protopopov A; Pollard J; Bahjat K; Wiederschain D; Sharma S
    Oncoimmunology; 2020 Sep; 9(1):1811605. PubMed ID: 33224628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.
    Morris JC; Tan AR; Olencki TE; Shapiro GI; Dezube BJ; Reiss M; Hsu FJ; Berzofsky JA; Lawrence DP
    PLoS One; 2014; 9(3):e90353. PubMed ID: 24618589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
    Huang Z; Xu Y; Hong W; Gong L; Chen K; Qin J; Xie F; Wang F; Tian X; Meng X; Feng W; Li L; Zhang B; Kang X; Fan Y
    Front Immunol; 2023; 14():1258573. PubMed ID: 37936687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
    Bauer TM; Santoro A; Lin CC; Garrido-Laguna I; Joerger M; Greil R; Spreafico A; Yau T; Goebeler ME; Hütter-Krönke ML; Perotti A; Juif PE; Lu D; Barys L; Cremasco V; Pelletier M; Evans H; Fabre C; Doi T
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies.
    Yang F; Paccaly AJ; Rippley RK; Davis JD; DiCioccio AT
    J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):479-494. PubMed ID: 33728546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial.
    Liu D; Zhou J; Wang Y; Li M; Jiang H; Liu Y; Yin X; Ge M; Xiang X; Ying J; Huang J; Zhang YQ; Cheng Y; Huang Z; Yuan X; Han W; Yan D; Wang X; Liu P; Wang L; Zhang X; Luo S; Liu T; Shen L
    BMC Med; 2022 Oct; 20(1):408. PubMed ID: 36280870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
    Hamid O; Chiappori AA; Thompson JA; Doi T; Hu-Lieskovan S; Eskens FALM; Ros W; Diab A; Spano JP; Rizvi NA; Wasser JS; Angevin E; Ott PA; Forgie A; Yang W; Guo C; Chou J; El-Khoueiry AB
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma.
    Liu D; Ma C; Lu P; Gong J; Ye D; Wang S; Peng P; Bai Y; Song Y; Chen J; Jiang O; Zhang G; Ba Y; Chen L; Pan J; Li Q; Zhang L; Gu S; Yin X; Cao B; Han W; Dong H; Guo J; Zhang H; Su H; Jiang Y; Ouyang W; Ma L; Sun Y; Zhang F; Lv J; Guo Y; Xu C; Qi J; Wang L; Wang X; Liu Z; Shen L
    Eur J Cancer; 2021 May; 148():1-13. PubMed ID: 33691262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort.
    Moreno V; Garrido P; Papadopoulos KP; De Miguel Luken MJ; Gil-Martin M; Aljumaily R; Rosen LS; Rietschel P; Mohan KK; Yoo SY; Stankevich E; Lowy I; Fury MG
    Lung Cancer; 2021 May; 155():151-155. PubMed ID: 33831732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.
    Leidner R; Conlon K; McNeel DG; Wang-Gillam A; Gupta S; Wesolowski R; Chaudhari M; Hassounah N; Lee JB; Ho Lee L; O'Keeffe JA; Lewis N; Pavlakis GN; Thompson JA
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37907221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors.
    Ma Y; Xue J; Zhao Y; Zhang Y; Huang Y; Yang Y; Fang W; Guo Y; Li Q; Ge X; Sun J; Zhang B; Zhang Y; Xiao J; Zhang L; Zhao H
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37263673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
    Piha-Paul SA; Geva R; Tan TJ; Lim DW; Hierro C; Doi T; Rahma O; Lesokhin A; Luke JJ; Otero J; Nardi L; Singh A; Xyrafas A; Chen X; Mataraza J; Bedard PL
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis.
    Paccaly AJ; Migden MR; Papadopoulos KP; Yang F; Davis JD; Rippley RK; Lowy I; Fury MG; Stankevich E; Rischin D
    Adv Ther; 2021 May; 38(5):2365-2378. PubMed ID: 33768419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
    Migden MR; Rischin D; Schmults CD; Guminski A; Hauschild A; Lewis KD; Chung CH; Hernandez-Aya L; Lim AM; Chang ALS; Rabinowits G; Thai AA; Dunn LA; Hughes BGM; Khushalani NI; Modi B; Schadendorf D; Gao B; Seebach F; Li S; Li J; Mathias M; Booth J; Mohan K; Stankevich E; Babiker HM; Brana I; Gil-Martin M; Homsi J; Johnson ML; Moreno V; Niu J; Owonikoko TK; Papadopoulos KP; Yancopoulos GD; Lowy I; Fury MG
    N Engl J Med; 2018 Jul; 379(4):341-351. PubMed ID: 29863979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors.
    Borazanci E; Schram AM; Garralda E; Brana I; Vieito Villar M; Spreafico A; Oliva M; Lakhani NJ; Hoffman K; Hallett RM; Maetzel D; Hua F; Hilbert J; Giblin P; Anido J; Kelly A; Vickers PJ; Wasserman R; Seoane J; Siu LL; Hyman DM; Hoff DV; Tabernero J
    ESMO Open; 2022 Aug; 7(4):100530. PubMed ID: 35921760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.
    Chiorean EG; LoRusso P; Strother RM; Diamond JR; Younger A; Messersmith WA; Adriaens L; Liu L; Kao RJ; DiCioccio AT; Kostic A; Leek R; Harris A; Jimeno A
    Clin Cancer Res; 2015 Jun; 21(12):2695-703. PubMed ID: 25724527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and action of transforming growth factor beta (TGFbeta1, TGFbeta2, TGFbeta3) in normal bovine ovarian surface epithelium and implications for human ovarian cancer.
    Nilsson E; Doraiswamy V; Parrott JA; Skinner MK
    Mol Cell Endocrinol; 2001 Sep; 182(2):145-55. PubMed ID: 11514049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors.
    Frentzas S; Kao S; Gao R; Zheng H; Rizwan A; Budha N; de la Hoz Pedroza L; Tan W; Meniawy T
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.